Let's Talk MND - Michael Thurn CEO PharmAust

Our guest this week is Michael Thurn the CEO and Managing Director of PharmAust, a clinical-stage biotechnology company. He tells us about Monepantel which is a well-known veterinary drug. It has been shown to have an effect on the abnormal accumulation of protein in cells. This accumulation is associated with motor neurone disease. Monepantel works by increasing the recycling and removal of excessive or abnormal proteins.  Results from phase 1 of this trial suggest that monepantel was well tolerated. In fact it showed a slowing in progression of MND.  In July of 2024 Monepantel has been included in the Healy ALS trials, in Boston, USA, which means the study will be fast tracked. To learn more about the studies please go to  https://www.pharmaust.com